China’s Best Shot: GSK, Novartis Gear Up For Vaccine Prime Time
This article was originally published in PharmAsia News
Executive Summary
With its large population, one-child policy and increasing emphasis on preventative care, China is poised for a vaccine boom. The catalyst for growth may come from the expected modernization of the country’s massive national immunization program.